Fresenius Medical Care AG & Co. KGaA: Dr. Carla Kriwet succeeds Rice Powell as CEO of the Management Board of Fresenius Medical Care
Fresenius Medical Care AG & Co. KGaA / Key word(s): Personnel
In today’s meeting the Supervisory Board of Fresenius Medical Care's General Partner unanimously appointed Dr. Carla Kriwet as CEO of the Management Board effective January 1, 2023. Dr. Carla Kriwet succeeds Rice Powell, who will step down from the Management Board in light of the age limit for members of the Management Board when his contract expires at the end of December 2022.
In her capacity as CEO of Fresenius Medical Care, Dr. Carla Kriwet will also be a member of the Management Board of Fresenius Management SE.
Person making the notification:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,171 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the Company focuses on expanding in complementary areas and in the field of critical care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
03-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Fresenius Medical Care AG & Co. KGaA
61352 Bad Homburg
+49 (0) 6172- 609 2525
+49 (0) 6172- 609 2301
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange
EQS News ID:
End of Announcement
DGAP News Service